OACC vs RLAY

Oaktree Acquisition Corp.

III Life Sciences (OACC) offers the better valuation at 195. 8x trailing P/E, making it the more compelling value choice. Analysts rate Relay Therapeutics, Inc. (RLAY) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Oaktree Acquisition Corp.

III Life Sciences (OACC) delivered a total return of +6. 1%, compared to -57. 6% for Relay Therapeutics, Inc. (RLAY). Over 10 years, the gap is even starker: OACC returned +6. 1% versus RLAY's -64. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Oaktree Acquisition Corp.

III Life Sciences (OACC) is the lower-risk stock at 0. 08β versus Relay Therapeutics, Inc. 's 1. 77β — meaning RLAY is approximately 2082% more volatile than OACC relative to the S&P 500. On balance sheet safety, Oaktree Acquisition Corp. III Life Sciences (OACC) carries a lower debt/equity ratio of 0% versus 6% for Relay Therapeutics, Inc. — giving it more financial flexibility in a downturn.

Oaktree Acquisition Corp.

III Life Sciences (OACC) is the more profitable company, earning 0. 0% net margin versus -1800. 6% for Relay Therapeutics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: OACC leads at 0. 0% versus -1971. 6% for RLAY. At the gross margin level — before operating expenses — RLAY leads at 76. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Oaktree Acquisition Corp.

III Life Sciences (OACC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 08)). Relay Therapeutics, Inc. (RLAY) carries a higher beta of 1. 77 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (OACC: +6. 1%, RLAY: -64. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (OACC (Financial Services) and RLAY (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: OACC is a small-cap quality compounder stock; RLAY is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.